Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
Cancer Lett
; 254(2): 265-73, 2007 Sep 08.
Article
en En
| MEDLINE
| ID: mdl-17449174
ABSTRACT
Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Proto-Oncogénicas
/
Proteínas ras
/
Neoplasias Pulmonares
/
Mutación
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer Lett
Año:
2007
Tipo del documento:
Article
País de afiliación:
Estados Unidos